Caris Life Sciences, the Irving-based next-generation AI biotech company and precision medicine pioneer, has reached a new agreement with pharmaceutical giant Moderna to support Moderna’s oncology novel therapeutics initiatives.
Caris said that it’s creating and delivering innovative solutions to “revolutionize healthcare and improve the human condition” using molecular science and AI.
“We’re thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,” David Spetzler, president of Caris Life Sciences, said in a statement. “The aggregate strength of our combined molecular, data science, and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna’s innovative medicines.”
Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses, along with claims data to improve development strategies for Moderna’s oncology pipeline. That includes facilitation of optimal clinical trial design, discovery of novel biomarkers, and characterization of resistance mechanisms.
Leveraging Caris’ clinico-genomic database
“Partnering with Caris Life Sciences will support Moderna’s oncology portfolio with clinico-genomics data from Caris’ industry-leading and comprehensive suite of integrated precision medicine capabilities,” Praveen Aanur, MD, the oncology therapeutic area head of Moderna, said in a statement.
Caris said it has developed the largest clinico-genomic database coupled with cognitive computing to “unravel the molecular complexity of disease.”
The Irving company says it was the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient,.
Beyond Irving, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia, and other international markets.
In January, Caris Life Sciences closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
-
The $110 million, 135,000 square-foot expansion at Pegasus Park—a regional hub for life sciences and biotechnology in North Texas—will offer prebuilt lab suites with the tools and flexible space needed for growth-stage life sciences entrepreneurs and companies. Demolition is underway and construction on Bridge Labs is set to begin soon, developers said.
-
Dallas-based alternative investment firm NexPoint has revealed details and renderings of its planned 200-acre TxS District, short for "Technology x Science." Centered on the former headquarters campus of EDS in Plano's Legacy development, the life sciences hub could eventually offer over 4 million square feet of lab, office, and therapeutic production space. "Not only would this project be a major economic catalyst for the region, but it would also establish North Texas as a leader in life sciences," says James Dondero, NexPoint founder and principal.
-
“Delivering these projects will help to increase the speed-to-market and meet the overwhelming demand for new medicines," said Richard Meserole, president of Fluor’s advanced technologies and life sciences business.
-
The report names Dallas-Fort Worth as "a top emerging life sciences market in terms of size, institutions, talent, and rapid growth, alongside Nashville and Atlanta." According to Chelsea Story, VP with CBRE’s Life Sciences practice in Dallas, "DFW has all of the pieces assembled to become a dominant force in the life sciences sector."
